Company intelligence / Profile preview

Tectora Therapeutics

Ownership: Private

Overview

Tectora Therapeutics is a privately held biotechnology company focused on developing differentiated oral small molecule medicines for immunology and inflammation. Co-founded in September 2026 by Schrödinger, New Enterprise Associates (NEA), and RA Capital Management, the company launched with a $55 million Series A financing round. Tectora's initial pipeline consists of two early-stage small molecule programs, SDGR-4594 and SDGR-8139, which were contributed by Schrödinger. The company leverages Schrödinger's physics-based computational chemistry platform and drug discovery expertise to advance these candidates toward clinical development.

Modalities: Small molecule
Industry: Biotech

Partnerships

Schrödinger

Beyond the preview

Go deeper on Tectora Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tectora Therapeutics.

Explore the full profile